Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [IR] SK hynix (000660 / SKHY) – Q1 2025 Earnings Presentation / 2025-04-24 IR Room
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Server DRAM · eSSD · Earnings Upgrades / 2026-04-09 Research
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | US ESS Surges · 4Q LFP Ramp-Up · Cyclical Bottom Passed / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Memory ASP · Earnings Upgrades · Valuation Appeal / 2026-03-16 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Biosimilar Growth · Facility Expansion · CMO Capacity Readiness / 2026-05-07 Research
  • [IR] SK hynix (000660 / SKHY) – Q4 2024 Earnings Presentation / 2025-01-23 IR Room
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Failure · Grabody Platforms · Intrinsic Value / 2026-04-28 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2025 Earnings Presentation / 2026-01-23 IR Room

[Research] Hanwha Ocean (042660) – SK Securities | Merchant Margin Surprise · Cost & Incentive Factors · Earnings Volatility / 2026-07-28

Posted on July 28, 2026August 22, 2026 By ksb220805@gmail.com

Brokerage : SK Securities

Analyst : Seunghan Han (R.A : Seoyoung Ko)

Investment Rating : BUY (Maintained)

Target Price : KRW 134,000 (Maintained)

Core Momentum : Sustained recurring profit expansion in merchant ships driven by high-margin 2024–2025 LNGC builds, alongside a balanced focus on total earnings volatility stemming from FX shifts, incentive costs, and fixed-cost absorption

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY Maintained, Target Price maintained at KRW 134,000 based on a Target P/E of 18.0x applied to 2028F EPS of KRW 7,422 (Current Price: KRW 88,800 as of July 27, 2026; Upside potential: 50.9%)
  • 2Q26 Earnings Summary: Consolidated Revenue stood at KRW 5.44 trillion (+65.2% YoY, +69.6% QoQ), Operating Profit reached KRW 736.1 billion (+98.0% YoY, +67.9% QoQ, OPM 13.5%), and Net Profit attributable to controlling interests came in at KRW 570.0 billion, beating market consensus (operating profit of KRW 533.5 billion) by approximately 38%.
  • FY2026 Annual Estimate Revisions (Previous → New):
    • Revenue: KRW 13.89 trillion → KRW 16.59 trillion (+19.4%)
    • Operating Profit: KRW 2.08 trillion → KRW 2.50 trillion (+20.4%)
    • Operating Margin (OPM): 14.9% → 15.1% (+0.2%p)
    • Net Profit (Controlling): KRW 1.76 trillion → KRW 2.09 trillion (+18.6%)
    • Net Profit Margin: 12.7% → 12.6% (-0.1%p)

🚀 2. [Market Opportunities & Business Outlook]

  • Merchant Vessel Earnings & Order Breakdown: In 2Q26, the merchant shipbuilding division posted an OPM of 22.7% without one-off gains, driven by: 1) increased working days and productivity gains, 2) structural cost reductions, 3) a rising construction mix of high-margin LNGCs ordered since 2024, and 4) positive FX translation effects. Revenue breakdown by order vintage stood at 13% for 2022, 21% for 2023, 45% for 2024, and 21% for 2025, with vessel type exposure consisting of LNG 69%, Container 8%, VLGC 8%, and VLCC 15%.
  • Offshore Division Turnaround: The offshore division achieved an operating turnaround, supported by the one-time recognition of ~KRW 1.5 trillion in revenue and associated provision reversals from the P79 FPSO project delivery.
  • Earnings Volatility & 2H Monitoring Factors: While recurring merchant profit improvements are expected to continue in 2H26 on high-price LNGC execution, target valuation multiples were lowered due to potential corporate earnings volatility from fewer 3Q working days, 2H incentive payouts, potential upward adjustments in estimated costs, FX fluctuations, and fixed-cost absorption in offshore and special ship units depending on incoming order volume.

📝 Editor’s Comment (Perspective)

The analyst views Hanwha Ocean as a shipbuilder demonstrating solid underlying merchant vessel profitability supported by high-margin LNGC construction and cost savings, while highlighting the need for a measured approach due to potential volatility across foreign exchange, incentive expenses, cost re-estimates, and naval/offshore fixed-cost burdens. This perspective balances the strong 2Q merchant surprise and offshore turnaround against potential cost variables and the continuity of consolidated earnings.

To evaluate whether this investment thesis continues to materialize, key verification points include whether merchant margins hold up during periods of reduced working days and incentive recognition in 2H26, the earnings impact of cost revisions and FX movements, and the pace of new contract awards in the offshore and special ship divisions to mitigate fixed overhead. These factors can be monitored through upcoming quarterly earnings releases, official IR materials, regulatory filings, and periodic financial reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Shipbuilding

Post navigation

Previous Post: [Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28
Next Post: [Research] Hanwha Ocean (042660) – Shinhan | Merchant Profit Level-Up · Special Ship Order Variables · Balanced Portfolio / 2026-07-28

Related Posts

  • [Research] Samsung Biologics (207940) – iM Securities | US Site Operation · K-CDMO Policy Support · Order Pipeline Optimization / 2026-04-23 Research
  • [Research] LIG D&A (079550) – iM Securities | Export Pipeline · CapEx & Hiring Expansion · Global Air Defense Growth / 2026-08-07 Research
  • [Research] Samsung SDI (006400) – Shinhan Securities | Profit Turnaround · ESS Margin Support · North America LFP Ramp-up / 2026-07-20 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Capex Discipline · Multi-Year LTA · Shareholder Returns / 2026-01-30 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Big Tech Backlogs · Memory Supply Tightness · Earnings Growth / 2026-07-14 Research
  • [Research] LIG D&A (079550) – Eugene Investment & Securities | Non-Cheongung Potential · High-margin Legacy Defense · Earnings Surprise / 2026-05-08 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Supply Constraints · Memory Pricing · LTA / 2026-04-24 Research
  • [Research] Celltrion (068270) – SK Securities | 2Q26 Re: Profitability Inflection Underway · Operating Leverage In Focus · Robust H2 Momentum / 2026-08-03 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Server DRAM · eSSD · Earnings Upgrades / 2026-04-09 Research
  • [IR] Samsung Electronics (005930) – Q2 2024 Earnings Presentation / 2024-07-31 IR Room
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Ramp-up · Business Scale Expansion · Revenue Visibility / 2026-07-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme